Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S241656 phase 1/2 study in selected myeloid malignancies
2025-525128-88-00Phase 2Authorised
- Sponsor
- Servier
- Start
- Aug 2026
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, open-label trial of bdtx-4933 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (2 arms), sponsored by Servier. Primary endpoints: Dose-limiting toxicities, Safety and tolerability and 2 more. Planned start Aug 2026; status: authorised.
02
Drugs
bdtx-4933
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on 2025-525128-88-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-525128-88-00.